Greenwich LifeSciences, Inc.GLSI
Price (close)
$18.10
Market cap
$265.7M
P/E
—
Revenue (TTM)
—
Net income
-$22.5M
Dividend yield
—
1-year total return
73.7%
Net margin
—
Revenue growth
—
Debt / equity
—
What Greenwich LifeSciences, Inc. does.
are a clinical-stage biopharmaceutical company focused on our Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an
immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface
receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M |
More on GLSI.
- Greenwich LifeSciences, Inc. summary
- Greenwich LifeSciences, Inc. financial statements
- Greenwich LifeSciences, Inc. key metrics
- Greenwich LifeSciences, Inc. health scores and style box
- Greenwich LifeSciences, Inc. earnings
- Greenwich LifeSciences, Inc. dividends
- Greenwich LifeSciences, Inc. valuation
- Greenwich LifeSciences, Inc. ownership and insiders
- Greenwich LifeSciences, Inc. peers
Figures from Greenwich LifeSciences, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.